Research Article

Diagnostic and Prognostic Value of Long Noncoding RNAs as Potential Novel Biomarkers in Intrahepatic Cholestasis of Pregnancy

Shaohan Zou,1 Shaojie Zhao,2 Jing Wang,2 Ruirui Dong,2 Ping Zou,2 Fengbing Liang,1 Ting ting Zhu,1 Tao Zhou,2 Na Li,2 Yan Zhang,2 Tiejun Wang,2 Minjian Chen,3,4 Conghua Zhou,5 Ting Zhang2,2 and Liang Luo6

1Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Key Laboratory of Reproductive Dysfunction Management of Zhejiang Province, Hangzhou 310000, China
2The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi 214002, China
3State Key Laboratory of Reproductive Medicine, Institute of Toxicology, School of Public Health, Nanjing Medical University, Nanjing 211166, China
4Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing 211166, China
5School of Computer Science and Telecommunication Engineering, Jiangsu University, Zhenjiang 212013, China
6The Affiliated Wuxi No.2 People’s Hospital of Nanjing Medical University, Wuxi 214002, China

Correspondence should be addressed to Ting Zhang; zhangting040715@163.com and Liang Luo; luoliang0916@163.com

Shaohan Zou and Shaojie Zhao contributed equally to this work.

Received 3 September 2020; Revised 22 January 2021; Accepted 4 February 2021; Published 27 February 2021

Academic Editor: A. Seval Ozgu-Erdinc

Copyright © 2021 Shaohan Zou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Long noncoding RNAs (lncRNAs) are a class of important regulators participating in various pathological processes. Until now, the role of lncRNAs in the occurrence and development of intrahepatic cholestasis of pregnancy (ICP) has rarely been investigated. The data from microarray screening revealed 58 upregulated and 85 downregulated lncRNAs and 47 upregulated and 71 downregulated mRNAs in ICP patients compared to healthy controls. Bioinformatics analysis revealed biological processes focused on lipid metabolism, apoptosis, cell cycle, cell differentiation, and oxidative stress. Furthermore, the expressions of three lncRNAs (ENST00000505175.1, ASO3480, and ENST00000449605.1) chosen for verification were significantly decreased and showed the diagnostic and prognostic value for ICP based on ROC analysis. This is the first study to report the specific role of lncRNAs in ICP, which may be helpful for the diagnosis and prognosis of ICP clinically.

1. Introduction

Intrahepatic cholestasis of pregnancy (ICP) is distinguished by elevated liver enzymes and serum bile acids and pruritus [1, 2]. ICP patients are at a high risk of spontaneous fetal distress, sudden intrauterine death, and preterm labor [3]. Both genetic and environmental factors participate in the interpretation of the cause of ICP [4]. Several studies of ICP have revealed altered genes and proteins in many role places, including oxidative stress, cell growth, apoptosis, lipid metabolism, and immune responses [5, 6]. Currently, the identification of ICP is verified by symptoms and the serum level of total bile acids (TBA). However, the specificity is still limited. Therefore, the rapid diagnosis and treatment of ICP are important in obstetrics.

Long noncoding RNAs (lncRNAs) are transcripts with no protein-coding capability longer than 200 nucleotides [7]. During the last decade, they have been widely...
acknowledged as crucial regulators of various diseases, such as cancer, cardiovascular diseases, and rheumatoid diseases [8, 9]. They are involved in many pathophysiological and physiological processes, such as chromatin remodeling, cell cycle progression, posttranscriptional processing, and gene transcription [10, 11]. It has been reported that some lncRNAs are highly expressed in several types of cancers which makes them a promising tool for disease diagnosis. Some other lncRNAs are related to patient survival which makes them suitable for the prognosis of cancer [12]. Until now, the role and related mechanism of lncRNAs in ICP are still not fully elucidated. Hu et al. have found that linc02527 is upregulated in placenta and serum from ICP patients, and in vitro experiment using HTR8 cells reveals that linc02527 promotes autophagy and cell proliferation, which indicates that linc02527 may be a potential target for ICP treatment [6]. However, the relation of lncRNAs and the occurrence and development of ICP are still far from clear, clarifying that the assignment of lncRNAs in ICP may aid in understanding the pathogenesis of ICP and may supply new determinants for the diagnosis, treatment, and prognosis of ICP.

In our study, we investigated the expression profiles of lncRNAs using serum from ICP patients and explored the diagnostic and prognostic value of differently expressed lncRNAs in ICP.

2. Materials and Methods

2.1. Study Population. A case-control study was carried out to identify maternal serum lncRNAs for the diagnosis and prognosis of ICP. This study recruited 54 pregnant women with ICP and 54 healthy pregnant women from Wuxi Maternity and Child Health Care Hospital, Nanjing Medical University, between October 2016 and September 2017. No ursodeoxycholic acid was administered before blood sample collection.

The criteria for diagnosing ICP and recruiting and excluding subjects were described previously [13]. ICP was diagnosed in women presenting with classical pruritus associated with liver dysfunction and raised serum total bile acids (TBA) (>10 μmol/L as moderate ICP, >40 μmol/L as severe ICP). All other causes of liver dysfunction, including preeclampsia, the HELLP (haemolysis, elevated liver enzymes, and low platelets) syndrome, acute fatty liver of pregnancy, primary biliary cirrhosis, viral hepatitis, and any ultrasound abnormality that may result in biliary obstruction were excluded. The characteristics of the patients and controls are in Table 1. All participants had signed written informed consent prior to recruitment, and the study protocol was approved by the Medical Ethics Committee of the Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University.

2.2. Sample Preparation. Peripheral blood (5 mL) was collected from each participant, and the serum was isolated within 4 h by centrifuge for 10 min at 4,000 rpm and then for 15 min at 12,000 rpm. The serum was removed carefully, divided into aliquots, and stored at −80°C. Total RNA was isolated by TRIzol (Invitrogen) and purified by a mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA), in the light of the manufacturer’s protocol. We determined the RNA concentration spectrophotometrically (NanoDrop ND-1000; Thermo Fisher Scientific, Waltham, MA, USA).

2.3. lncRNA Microarray. The global profiling of human lncRNAs and protein-coding transcripts was done with the CapitalBio Technology Human lncRNA Array v4. According to the manufacturer’s standard protocols, the sample was prepared and microarray hybridization was done. We analyzed the acquired array images by Agilent Feature Extraction software (ver. 11.0.1.1). Summarization, standardization, and quality control of data were carried out by

| Variable                  | Screening samples | Validation samples |
|---------------------------|-------------------|--------------------|
| Maternal age (y)          | ICP (n = 4)       | Control (n = 4)     | P value | ICP (n = 54) | Control (n = 54) | P value |
| 26.50 ± 3.87              | 27.2 ± 1.50       | 0.231              |         | 28.90 ± 6.32 | 26.1 ± 4.87       | 0.220  |
| Gestational weeks         | 37.85 ± 0.77      | 38.72 ± 0.63       | 0.076   | 37.93 ± 0.93 | 38.92 ± 0.95       | 0.041  |
| TBA (μmol/L)              | 58.33 ± 12.4*     | 3.51 ± 1.72        | 0.003   | 68.93 ± 50.35* | 5.34 ± 3.17       | 0.019  |
| ALT (IU/L)                | 68.25 ± 24.76*    | 17.01 ± 8.37       | 0.016   | 108.65 ± 101.44* | 16.1 ± 7.68       | 0.018  |
| AST (IU/L)                | 82.71 ± 29.53*    | 19.36 ± 5.42       | 0.028   | 106.78 ± 96.11* | 16.92 ± 8.34       | 0.018  |

TBA: total bile acid; ALT: alanine transaminase; AST: aspartate transaminase; statistical analysis was performed using t-tests; *P < 0.05 was considered significant.

2 BioMed Research International

Table 2: Primer sequences used in validation of lncRNAs.

| lncRNA                        | Forward primer (5′-3′) | Reverse primer (5′-3′) |
|-------------------------------|-----------------------|-----------------------|
| ENST00000505175.1             | GCCCGAGTGACCTTGACCCTT | TTGCTGCTCTTTATGCTCAC  |
| ASO3480                       | TTGATGGCTGCGCATGCTCT  | CCAATGTTAGGCAACACATC  |
| ENST00000449605.1             | CAGCGTCGCGCCAACATAGTA | CCTGGGGCTTAAAACGATGCT |
| ST00000503615.1               | GCTCGCTGATTTCTAGACTT  | GACAGCGCGTCACATTTC    |
| RNA95791|RNS_873_113                | ATAAAAGGAGTTCGGATGTC  | TTTTAAACCCTTTAAGAATC  |
GeneSpring v13.0 (Agilent). Scatterplot filtering was used to identify those differentially expressed lncRNAs and mRNAs.

2.4. qPCR Validation. From 143 differentially expressed lncRNAs, we chose five respective lncRNAs with good consistency and small within-group and large between-group differences. Among these, RNA95791|RNS_873_113 and ENST00000503615.1 could not be detected in blood. Then, the expressions of another three lncRNAs were calculated by qRT-PCR (TaKaRa Bio, Inc., Tokyo, Japan) on an ABI 7500 (Applied Biosystems, Foster City, CA, USA). We normalized the expression level to miR-39 [14]. The
primers used for qPCR of the lncRNAs are listed in Table 2. We used the $2^{-\Delta\Delta Ct}$ method to calculate the relative expression of lncRNAs.

2.5. Bioinformatics Analysis. We got the mRNA and lncRNA microarray data from CapitalBio Corp. (Beijing, China). We selected the differentially expressed genes using thresholds of $\geq 2$ and $\leq -2$ times variation. Further analysis was done with hierarchical clustering with average linkage [15]. We use Gene Ontology (GO) analysis and pathway analysis to determine the potential function of maladjusted lncRNA and the role of differentially expressed mRNA.

2.6. Statistical Analysis. Statistical analyses were carried out by GraphPad 8.0 (GraphPad Software Inc., La Jolla, CA, USA) and SPSS 16.0 (SPSS Inc., Chicago, IL, USA). Data
Table 3: Part of differentially expressed lncRNAs in the serum from pregnant women with ICP (P) compared to healthy pregnant women (C).

| lncRNA ID | Fold change (P : C ratio) | P value | Regulation |
|-----------|---------------------------|---------|------------|
| RNA95791|RNS_873_113 | 6.96 | 1.06 * 10^{-3} | Up |
| ENST0000446102.1 | 6.40 | 4.29 * 10^{-5} | Up |
| ENST0000439804.1 | 4.08 | 2.06 * 10^{-2} | Up |
| ENST0000534653.1 | 5.87 | 2.40 * 10^{-4} | Up |
| ENST0000609910.1 | 5.15 | 2.04 * 10^{-2} | Up |
| ENST0000483023.1 | 4.96 | 7.27 * 10^{-3} | Up |
| ENST0000503615.1 | 2.70 | 1.78 * 10^{-2} | Up |
| ENST0000584829.1 | 0.153 | 3.02 * 10^{-2} | Down |
| ENST00005023759.1 | 0.164 | 1.11 * 10^{-2} | Down |
| TCONS_00011955 | 0.171 | 3.34 * 10^{-2} | Down |
| TCONS_00009146 | 0.240 | 3.56 * 10^{-2} | Down |
| ENST0000449605.1 | 0.242 | 4.57 * 10^{-2} | Down |
| HIT000248174 | 0.317 | 4.84 * 10^{-2} | Down |
| ENST0000604818.1 | 0.193 | 2.26 * 10^{-2} | Down |
| TCONS_00006708 | 0.338 | 4.93 * 10^{-2} | Down |
| ENST0000600160.1 | 0.266 | 2.17 * 10^{-2} | Down |
| ASO3480 | 0.267 | 4.58 * 10^{-2} | Down |
| ENST0000536898.1 | 0.198 | 3.84 * 10^{-2} | Down |
| HIT000430355 | 0.200 | 2.64 * 10^{-2} | Down |
| ENST0000505175.1 | 0.323 | 2.92 * 10^{-2} | Down |

P is the probability of the difference of lncRNA expression between pregnant women with ICP (P) and healthy pregnant women (C). P < 0.05 was considered statistically significant. The chosen differentially expressed lncRNAs with verification by qRT-PCR were in italic.

were performed as means ± SD for a minimum of three independent experiments in triplicate. Independent Student's t-test and one-way ANOVA were used to contrast different teams. We used ROC curve analysis to assess the ability of biomarkers to distinguish the disease group from the control group. A level of P < 0.05 was considered statistically significant.

3. Results

3.1. Screening and Identification of Differentially Expressed lncRNAs and mRNAs in ICP. The expression profiles were compared from ICP patients and healthy controls using the CapitalBio Technology Human lncRNA Array v4. The hierarchical clustering analysis, scatterplot, and volcano plot from microarray screening showed that there were 58 upregulated and 85 downregulated lncRNAs, while 47 upregulated and 71 downregulated mRNAs in the ICP group compared to the HC group (Figures 1 and 2). Table 3 shows the information of the aberrantly presented lncRNAs. From 143 differentially expressed lncRNAs, the 5 differentially expressed lncRNAs were chosen for verification by qRT-PCR in the serum, due to their expressions showing little internal difference within the groups but pronounced difference among the groups. Among these, RNA95791 and RNS_873_113 were not detected in the serum of the ICP group. Another three lncRNAs, ENST0000505175.1, ASO3480, and ENST0000449605, were significantly downregulated in the ICP group contrasted with the control (Figure 3).

3.2. Bioinformatics Analysis of Differentially Expressed lncRNAs and mRNAs in ICP. To find the possible enrichment of biofunctions of those differentially expressed lncRNAs and mRNAs, we did pathway analysis using Gene Ontology (GO) terms (Table 4). It showed that the significantly enriched terms include the cell cycle process, fatty acid metabolic process, apoptotic signaling pathway, and oxidative stress. Furthermore, the aberrantly expressed mRNAs in the ICP group are HAND1 (heart- and neural crest derivative-expressed protein 1), MRPS16, and AQP2 (Aquaporin 2). The results revealed the association of differentially expressed lncRNAs and mRNAs in ICP.

3.3. The Potential Diagnostic Value of Serum lncRNAs for ICP. To evaluate the diagnostic value of lncRNAs, the association between ENST0000505175.1, ASO3480, ENST0000449605.1, and TBA was analyzed using Pearson correlation analysis. It showed that the levels of ENST0000505175.1, ASO3480, and ENST0000449605.1 were positively associated with the TBA (R = 0.401, P < 0.001; R = 0.319, P = 0.0009; and R = 0.300, P = 0.0018, respectively) (Figure 4). Furthermore, the sensitivity and specificity of lncRNAs for ICP diagnosis were evaluated. The ROC curves of ENST0000505175.1/ASO3480/ENST0000449605.1 show strong separation between ICP and non-ICP groups, with an area under the curve (AUC) of 0.731 (95% confidence interval, 0.675–0.787) for ENST0000505175.1, 0.812 (95% confidence interval, 0.756–0.865) for ASO3480, 0.974 (95% confidence interval, 0.934–1.000) for ENST0000449605.1, and 0.934 (95% confidence interval, 0.865–0.997) for ENST0000505175.1/ASO3480/ENST0000449605.1, respectively (Figure 5). The results revealed such three lncRNAs have a diagnostic value for ICP, which can be a supplement for TBA diagnosis.

3.4. The Potential Prognostic Value of Serum lncRNAs for ICP. To evaluate the prognostic value of lncRNAs, the association between ENST0000505175.1, ASO3480, ENST0000449605.1, and perinatal outcomes of ICP was analyzed using the chi-squared test. The lncRNA expression was normalized by log2 transformation. We used the median serum lncRNA level as the critical value in the samples [16]. The group with low lncRNA expression had worse perinatal outcomes, such as meconium-stained amniotic fluid, fetal distress, and premature delivery (Table 5). The difference between the groups was significant. The results revealed that such three lncRNAs have a prognostic value for ICP, which can be a potential monitor for ICP treatment.
Figure 3: Real-time PCR confirmed three differentially expressed lncRNAs in 54 pairs of ICP patients and healthy controls. (a) ENST00000505175.1 was notably decreased in ICP compared with controls (\( P = 0.0196 \)). (b) ASO3480 was markedly decreased in ICP compared with controls (\( P = 0.0203 \)). (c) ENST00000449605.1 was obviously decreased in ICP compared with controls (\( P = 0.0224 \)).

Table 4: GO and pathway enriched analyses for differentially expressed lncRNAs and mRNAs.

| Category                          | Subcategory                                               | \( P \) value     | No. of genes | No. of target genes |
|-----------------------------------|-----------------------------------------------------------|-------------------|--------------|---------------------|
| Pathways                          | Primary bile acid biosynthesis                            | \( 1.44 \times 10^{-2} \) | 36           | 6                   |
|                                   | Oxidative stress                                          | \( 1.56 \times 10^{-2} \) | 69           | 15                  |
|                                   | Fatty acid biosynthesis                                   | \( 2.06 \times 10^{-2} \) | 53           | 9                   |
|                                   | Inflammation mediated by chemokine and cytokine signaling pathway | \( 4.59 \times 10^{-2} \) | 77           | 15                  |
| GO: biological function           | Response to fatty acid                                    | \( 5.81 \times 10^{-3} \) | 61           | 13                  |
|                                   | Cell cycle                                                | \( 6.56 \times 10^{-3} \) | 61           | 15                  |
|                                   | Neuron apoptotic process                                  | \( 8.41 \times 10^{-3} \) | 70           | 15                  |
|                                   | Endothelial cell proliferation                            | \( 1.22 \times 10^{-2} \) | 72           | 14                  |
|                                   | Cell cycle process                                        | \( 1.46 \times 10^{-2} \) | 48           | 10                  |
|                                   | Apoptotic DNA fragmentation                               | \( 1.66 \times 10^{-2} \) | 63           | 14                  |
|                                   | Mitotic cell cycle arrest                                 | \( 1.96 \times 10^{-2} \) | 63           | 12                  |
|                                   | Adaptive immune response                                 | \( 2.04 \times 10^{-2} \) | 38           | 8                   |
|                                   | Cell cycle checkpoint                                     | \( 2.19 \times 10^{-2} \) | 69           | 15                  |
|                                   | Activation of cysteine-type endopeptidase activity involved in apoptotic process | \( 2.71 \times 10^{-2} \) | 70           | 15                  |
|                                   | Cell differentiation                                      | \( 2.86 \times 10^{-2} \) | 44           | 10                  |
|                                   | Very long-chain fatty acid metabolic process              | \( 3.02 \times 10^{-2} \) | 29           | 6                   |
|                                   | Innate immune response                                   | \( 3.22 \times 10^{-2} \) | 75           | 15                  |
|                                   | Long-chain fatty acyl CoA biosynthetic process            | \( 3.25 \times 10^{-2} \) | 60           | 12                  |
|                                   | Intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | \( 3.35 \times 10^{-2} \) | 57           | 13                  |
|                                   | Extrinsic apoptotic signaling pathway                    | \( 3.56 \times 10^{-2} \) | 54           | 9                   |
|                                   | Oxidative stress                                          | \( 3.58 \times 10^{-2} \) | 67           | 14                  |
|                                   | Cysteine-type endopeptidase activity involved in apoptotic process | \( 3.78 \times 10^{-2} \) | 70           | 15                  |
|                                   | Fatty acid metabolic process                              | \( 3.86 \times 10^{-2} \) | 60           | 11                  |
|                                   | Fatty acid biosynthetic process                           | \( 4.12 \times 10^{-2} \) | 29           | 6                   |
|                                   | Intrinsic apoptotic signaling pathway                    | \( 4.72 \times 10^{-2} \) | 72           | 14                  |
Figure 4: The correlation of serum lncRNA level and TBA in ICP patients. (a) ENST00000505175.1 ($R = 0.401$, $P < 0.0001$), (b) ASO3480 ($R = 0.319$, $P = 0.0009$), and (c) ENST00000449605.1 ($R = 0.300$, $P = 0.0018$).

Figure 5: Diagnostic value of serum lncRNAs in ICP patients. (a) ENST00000505175.1, (b) ASO3480, (c) ENST00000449605.1, (d) ROC curve of the union of the 3 lncRNAs by multiple logistic regression analysis. The union of the 3 lncRNAs (ENST00000505175.1, ASO3480, and ENST00000449605.1) yielded the largest AUC.
and in some cases [18, 19]. Therefore, it is significant to find novel biomarkers as a supplement for TBA diagnosis.

Circulating lncRNAs caused increasing adversity as a novel diagnostic tool due to the relatively noninvasive nature of their gathering [20, 21]. Moreover, they are easy to amplify and not susceptible to denaturation or modification. For example, lncRNA HOTAIR in the serum/plasma of pancreatic cancer patients is a diagnostic and prognostic marker [22]. Zhang et al. have revealed that the lncRNA MALAT1 is a new biomarker for predicting gestational diabetes [23]. MALAT1 can also be used to predict metastasis and survival in patients with early-stage non-small-cell lung cancer [24]. A few of lncRNAs were verified in the human placenta, which is reported to regulate the response of the host to viral infection in human placental progenitor cells [25]. Yet, the expression and function of lncRNAs in the occurrence and development of ICP are still not clear. In this study, we found 143 differentially expressed lncRNAs using a CapitalBio Technology Human lncRNA Array v4 and identified three lncRNAs using qPCR. Bioinformatics technology revealed that target mRNA is mainly enriched in some processes such as cell cycle, fatty acid metabolism, apoptotic signaling, and oxidative stress [26–29]. According to the software prediction, the transcription factor of lncRNA ENST00000505175.1 is Oct-1 which participates in regulating a variety of physiological and pathological processes [30]. At present, studies have shown that Oct-1 is involved in the regulation of gastric cancer, colorectal cancer, ovarian cancer, and other cancers [31, 32]. In cancer, Oct-1 advanced the proliferation, migration, and invasion of cancer cells by regulating ERK and other signaling pathways [5, 33–35]. However, the detailed mechanism of such three lncRNAs would be further investigated.

Furthermore, the diagnostic and prognostic values of ENST00000505175.1, ASO3480, and ENST00000449605.1 in ICP were evaluated. We built ROC curves and computed the AUCs, which were 0.731, 0.798, and 0.812, respectively. Of note, the AUC (0.865) increased when we combined the three lncRNAs by multiple logistic regression analysis, indicating that the union of three lncRNAs is a more reliable ICP diagnostic marker. The prognostic significance of the serum lncRNAs in different risk subgroups based on meconium-stained amniotic fluid, fetal distress, and premature delivery was assessed, and such three lncRNAs appeared to be negative prognostic factors for ICP risk. The patients with higher serum concentrations of lncRNAs had worse pregnancy outcomes than those with lower serum concentrations especially when the three lncRNAs are used together, concluding that serum concentrations of the three lncRNAs could serve as a feasible prognostic biomarker of ICP.

However, our preliminary research only showed the differential expressions of these three lncRNAs in ICP patients and their potential significance. Whether such three lncRNAs can be finally applied to the clinic and a subgroup analysis between the patients with TBA levels ≥ 40 μmol/L and TBA levels < 40 μmol/L requires a large sample of data surveys and the related optimization designs. In addition, the functions of such three lncRNAs in ICP are still in progress, and further basic research is needed.

### 4. Discussion

Epidemiological studies indicate that the prevalence of ICP is increasing due to the change in eating habits and living environments. ICP can cause premature delivery, meconium-stained amniotic fluid, unexplained fetal death, and postpartum hemorrhage of pregnant women [17]. Therefore, an early, accurate diagnosis of ICP is essential. Currently, ICP is diagnosed using the serum TBA level; elevation of TBA is the most frequent laboratory abnormality associated with ICP and the most sensitive marker for ICP. However, the TBA level is normal in the ICP patients with low pruritus in some cases [18, 19]. Therefore, it is significant to find novel biomarkers as a supplement for TBA diagnosis.

### 5. Conclusions

In summary, the serum level of the three lncRNAs may be used as the potential biomarkers of ICP. Combining the serum lncRNA levels with clinical markers commonly used in ICP, such as TBA, alanine aminotransferase, and...
glycocholic acid, may improve the diagnosis of ICP and merits further investigation.

**Data Availability**

The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request.

**Conflicts of Interest**

No author has any possible competing interest.

**Authors’ Contributions**

Ting Zhang and Liang Luo planned experiments. Jing Wang, Ping Zou, Ruirui Dong, Shaohan Zou, Shaojie Zhao, Na Li, Yao Wang, Yan Zhang, Tiejun Wang, Zhong Chen, Fengbing Liang, and Ting ting Zhu performed experiments. Minjian Chen, Conghua Zhou, and Tao Zhou analyzed data. Tao Zhou and Ruirui Dong contributed reagents or other essential materials. Jing Wang, Ruirui Dong, and Ping Zou wrote the paper. Shaohan Zou, and Shaojie Zhao contributed equally to this work.

**Acknowledgments**

This work was supported by the National Natural Science Foundation of China (grant nos. 81671489 and 81401222), Major Research Foundation of Jiangsu Science and Technology Department (grant no. BE2017628), Jiangsu Provincial Medical Youth Talent of the Project of Invigorating Health Care through Science, Technology and Education (QNRC2016167), and Foundation of Wuxi City Health and Family Planning (grant nos. MS201501 and Q201505). The authors thank all of the women who provided samples for the study.

**References**

[1] A. M. Wood, E. G. Livingston, B. L. Hughes, and J. A. Kuller, "Intrahepatic cholestasis of pregnancy: a review of diagnosis and management," *Obstetrical & Gynecological Survey*, vol. 73, no. 2, pp. 103–109, 2018.

[2] C. Ovadia and C. Williamson, "Intrahepatic cholestasis of pregnancy: recent advances," *Clinics in Dermatology*, vol. 34, no. 3, pp. 327–334, 2016.

[3] A. E. Kremer, K. Wolf, and S. Ständer, "Intrahepatische Schwangerschaftscholestase," *Hautarzt*, vol. 68, no. 2, article 3923, pp. 95–102, 2017.

[4] A. Floreani and M. T. Gervasi, "New insights on intrahepatic cholestasis of pregnancy," *Clinics in Liver Disease*, vol. 20, no. 1, pp. 177–189, 2016.

[5] T. Zhang, C. Zhao, L. Luo et al., "High concentration of taurocholic acid induced apoptosis in htr-8/svneo cells via overexpression of erp29 and activation of p38," *Placenta*, vol. 35, no. 7, pp. 496–500, 2014.

[6] J. Hu, L. Liu, Y. Gong et al., "Linc02527 promoted autophagy in intrahepatic cholestasis of pregnancy," *Cell Death & Disease*, vol. 9, no. 10, 2018.

[7] J. Jarroux, A. Morillon, and M. Pinskaya, “History, discovery, and classification of Incrnas,” *Advances in Experimental Medicine and Biology*, vol. 1008, pp. 1–46, 2017.

[8] M. M. Kumar and R. Goyal, "Lncrna as a therapeutic target for angiogenesis," *Current Topics in Medicinal Chemistry*, vol. 17, no. 15, pp. 1750–1757, 2017.

[9] X. Li, R. Liu, J. Yang et al., “The role of long noncoding rna h19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice,” *Hepatology*, vol. 66, no. 3, pp. 869–884, 2017.

[10] M. Huarte, "The emerging role of Incrnas in cancer," *Nature Medicine*, vol. 21, no. 11, pp. 1253–1261, 2015.

[11] W. Liu and C. Ding, "Roles of Incrnas in viral infections," *Frontiers in Cellular and Infection Microbiology*, vol. 7, p. 205, 2017.

[12] A. A. Yarmishyn and I. V. Kurochkin, "Long noncoding rnas: a potential novel class of cancer biomarkers," *Frontiers in Genetics*, vol. 6, p. 145, 2015.

[13] T. Zhang, Y. Guo, X. Guo et al., "Comparative proteomics analysis of placenta from pregnant women with intrahepatic cholestasis of pregnancy," *PloS One*, vol. 8, no. 12, article e83281, 2013.

[14] P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., "Circulating micrornas as stable blood-based markers for cancer detection," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 30, pp. 10513–10518, 2008.

[15] M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein, "Cluster analysis and display of genome-wide expression patterns," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 25, pp. 14863–14868, 1998.

[16] J. Yuan, R. Dong, F. Liu et al., "The mir-183/182/96 cluster functions as a potential carcinogenic factor and prognostic factor in kidney renal clear cell carcinoma," *Experimental and Therapeutic Medicine*, vol. 17, no. 4, pp. 2457–2464, 2019.

[17] C. Williamson and V. Geenes, "Intrahepatic cholestasis of pregnancy," *Obstetrics and Gynecology*, vol. 124, no. 1, pp. 120–133, 2014.

[18] J. K. Mays, "The active management of intrahepatic cholestasis of pregnancy," *Current Opinion in Obstetrics & Gynecology*, vol. 22, no. 2, pp. 100–103, 2010.

[19] M. Martinefski, M. Contin, S. Lucangioli, M. B. Di Carlo, and V. Tripodi, "In search of an accurate evaluation of intrahepatic cholestasis of pregnancy," *Scientifica (Cairo)*, vol. 2012, article 10518, 2012.

[20] T. Kishikawa, M. Otsuka, M. Ohno, T. Yoshikawa, A. Takata, and K. Koike, "Circulating rnas as new biomarkers for detecting pancreatic cancer," *World Journal of Gastroenterology*, vol. 21, no. 28, pp. 8527–8540, 2015.

[21] Z. Wang, M. Tan, G. Chen, Z. Li, and X. Lu, "Lncrna sox2-ot is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating sox2," *IUBMB Life*, vol. 69, no. 11, pp. 867–876, 2017.

[22] K. Kim, I. Jutooru, G. Chadalapaka et al., "Hotair is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer," *Oncogene*, vol. 32, no. 13, pp. 1616–1625, 2013.

[23] Y. Zhang, H. Wu, F. Wang, M. Ye, H. Zhu, and S. Bu, "Long non-coding rna malat1 expression in patients with gestational diabetes mellitus," *International Journal of Gynaecology and Obstetrics*, vol. 140, no. 2, pp. 164–169, 2018.
[24] P. Ji, S. Diederichs, W. Wang et al., “MALAT-1, a novel non-coding RNA, and thymosin β 4 predict metastasis and survival in early-stage non-small cell lung cancer,” *Oncogene*, vol. 22, no. 39, pp. 8031–8041, 2003.

[25] I. Penkala, J. Wang, C. M. Syrett, L. Goetzl, C. B. Lopez, and M. C. Anguera, "Lncrhoxf1, a long noncoding rna from the x chromosome that suppresses viral response genes during development of the early human placenta," *Molecular and Cellular Biology*, vol. 36, no. 12, pp. 1764–1775, 2016.

[26] D. Koul, Y. Takada, R. Shen, B. B. Aggarwal, and W. K. Yung, "PTEN enhances TNF-induced apoptosis through modulation of nuclear factor-κB signaling pathway in human glioma cells," *Biochemical and Biophysical Research Communications*, vol. 350, no. 2, pp. 463–471, 2006.

[27] B. B. Aggarwal, "Signalling pathways of the tnf superfamily: a double-edged sword," *Nature Reviews. Immunology*, vol. 3, no. 9, pp. 745–756, 2003.

[28] S. Chao, L. Xiaojun, W. Haizhen et al., "Lithocholic acid activates mtor signaling inducing endoplasmic reticulum stress in placenta during intrahepatic cholestasis of pregnancy," *Life Sciences*, vol. 218, pp. 300–307, 2019.

[29] W. Wang, J. Liu, I. Qi, J. Zhang, Q. Zhu, and C. Qin, "Rlip76 increases apoptosis through akt/mtor signaling pathway in gastric cancer," *Oncology Reports*, vol. 36, no. 4, pp. 2216–2224, 2016.

[30] C. Zhou, Y. Tong, K. Wawrowsky, S. Bannykh, I. Donangelo, and S. Melmed, "Oct-1 induces pituitary tumor transforming gene expression in endocrine tumors," *Endocrine-Related Cancer*, vol. 15, no. 3, pp. 817–831, 2008.

[31] K. Vazquez-Arreguin and D. Tantin, "The oct1 transcription factor and epithelial malignancies: old protein learns new tricks," *Biochimica et Biophysica Acta*, vol. 1859, no. 6, pp. 792–804, 2016.

[32] K. Szekeres, R. Koul, J. Mauro, M. Lloyd, J. Johnson, and G. Blanck, "An oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with raji b-cells: towards a model of the cancer cell/b-cell microenvironment," *Experimental and Molecular Pathology*, vol. 97, no. 3, pp. 585–589, 2014.

[33] J. Qian, X. Kong, N. Deng et al., "Oct1 is a determinant of synbindin-related erk signalling with independent prognostic significance in gastric cancer," *Gut*, vol. 64, no. 1, pp. 37–48, 2015.

[34] S. Ozkan, Y. Ceylan, O. V. Ozkan, and S. Yildirim, "Review of a challenging clinical issue: intrahepatic cholestasis of pregnancy," *World Journal of Gastroenterology*, vol. 21, no. 23, pp. 7134–7141, 2015.

[35] S. P. Larson, O. Kovilam, and D. K. Agrawal, "Immunological basis in the pathogenesis of intrahepatic cholestasis of pregnancy," *Expert Review of Clinical Immunology*, vol. 12, no. 1, pp. 39–48, 2015.